Health News Releases

June 19, 2024 16:55

Galderma Granted Key Manufacturing License Updates for New Biologics Capabilities at Its Center of Excellence

Galderma today announced that the Swedish Medical Products Agency (Läkemedelsverket) issued key manufacturing license updates that will allow the company to pursue its ambitious growth and innovation

June 19, 2024 15:15

Kirin Holdings Commences Tender Offer To Make FANCL A Wholly-Owned Subsidiary

Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO: 2503) has decided to acquire additional shares of common stock of FANCL Corporation (FANCL) (TOKYO: 4921) through a tender offer and share warr

June 19, 2024 10:00

Medidata Launches Clinical Data Studio, Leveraging AI to Modernize the Data Experience in Clinical Trials

Medidata (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.medidata.com%2Fen%2F&esheet=54053800&newsitemid=20240618137167&lan=en-US&anchor=Medidata&index=1&md5=9b4ee92db6a3a74cfb7

June 18, 2024 15:35

Carestream Secures Crucial Business Partner Agreement in Peru

Carestream Health recently secured an agreement with Distribuidora Diagnostica Medica SAC (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fdmdperu.com%2F&esheet=54063578&newsitemid=2

June 18, 2024 09:05

Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54062720&newsitemid=20240617592767&lan=en-US&anchor=TSE%3A4

June 16, 2024 10:00

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2F&esheet=54061414&newsitemid=20240614852542&lan=en-US&anchor=TSE%3A4502%2FNYSE%

June 13, 2024 14:15

RegenLab France Receives Prestigious EU-EIB Innovation Champion Award

RegenLab (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftrack.regenlab.com%2Fe%2F915601%2Ffr-accueil-%2Fnh859%2F499945919%2Fh%2FMJGMMXyPSguyCEA8gEgmux2pgRtnhNF3rpVyUTCRZ9Y&esheet=5

June 12, 2024 10:25

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

AOP Orphan Pharmaceuticals GmbH (AOP Health) continues a successful clinical research program in hematology/oncology with two abstracts accepted for presentation at the European Hematology Association

June 07, 2024 11:55

Erbe Elektromedizin inaugurates new competence center for medical instruments in Rangendingen, Germany, and expands its capacities for customers all over the world

Erbe Elektromedizin has inaugurated a new production and development building in Rangendingen, Germany, after three years of construction. At 90 million euros, the new 25,000 m² building is the larges

June 05, 2024 11:20

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain H Chain-Only Antibodies” in the Journ

June 04, 2024 10:05

Germans Trias i Pujol Hospital in Spain Launches Telehealth and Remote Patient Management Program Using Masimo W1® Medical Watches and Radius VSM™ Wearable Continuous Vital Signs Monitors

Masimo (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.masimo.com&esheet=54024712&newsitemid=20240602519106&lan=en-US&anchor=Masimo&index=1&md5=2fa389b04192756b6c102775397cd8f2)

June 04, 2024 09:32

Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment

Merck, a leading science and technology company, today shared updates on the company’s oncology pipeline and focused approach to the research and development of potential new medicines designed to imp

June 04, 2024 08:57

Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo

Takeda (TSE: 4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54024400&newsitemid=20240531655762&lan=en-US&anchor=TSE%3A

June 02, 2024 15:30

Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024

Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, announced data from an ongoing Phase 1 study of AC699 monotherapy in patients with

June 02, 2024 13:35

Morinaga Milk’s New Research Breakthrough Backed the Superiority of its Human-Residential Bifidobacteria (HRB) Strains in Metabolizing Toxin Precursor in the Gut

Morinaga Milk Industry Co., Ltd. (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.morinagamilk.co.jp%2Fenglish%2F&esheet=54016718&newsitemid=20240530532346&lan=en-US&anchor=Morina

June 02, 2024 13:33

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda (TSE:4502/NYSE:TAK (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54024414&newsitemid=20240531914145&lan=en-US&anchor=TSE%3A4

June 02, 2024 13:20

UAE Commits Additional $6.26b in Industrial Offtakes

Government enterprises and private companies in the UAE committed an additional $6.26 billion to local manufacturing during the Make it in the Emirates (MIITE) Forum, which concluded on Tuesday. Organ

May 31, 2024 15:05

Parse Biosciences Launches Trailmaker Data Analysis Platform to Simplify Single Cell Sequencing

Parse Biosciences (https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.parsebiosciences.com&esheet=54020000&newsitemid=20240530324847&lan=en-US&anchor=Parse+Biosciences&index=1&md5=af

May 31, 2024 15:00

Rhea Launches with Senior Advisory Panel, Growth Acquisitions and Strategic Partnerships to Advance Fertility Journeys for the Modern Family

Rhea (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.rhea-fertility.com%2F&esheet=54023155&newsitemid=20240530629751&lan=en-US&anchor=Rhea&index=1&md5=6bdc47f71fce37fda87be39181

May 30, 2024 16:45

JJP Biologics Announces Positive Decision to Execute a First-in-Human Clinical Trial of Anti-Inflammatory mAb JJP-1212 (anti-CD89)

JJP Biologics, a private biopharmaceutical company developing innovative antibody-based therapies, announces a positive decision, issued by the European Medicines Agency, on the Clinical Trial Applica

May 30, 2024 16:05

Asymchem Welcomes Franck Mevellec as Senior Director, Business Development

Asymchem (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fasymchem.com%2F&esheet=54019791&newsitemid=20240529046363&lan=en-US&anchor=Asymchem&index=1&md5=1c205c848b9ccf2653c34e49187b

May 30, 2024 14:55

Lenovo Powers AI Avatars to Explore the Role of Technology in Mental Health

Today, Lenovo™ released the newest iteration of its Work For Humankind (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Flenovowfh.com%2F&esheet=54018442&newsitemid=20240528448000&lan

May 30, 2024 10:15

Merck Signs MoU with KAIST to Advance Scientific Collaboration

Merck, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with the Korea Advanced Institute of Science and Technology (KAIST). The academia-industry c

May 30, 2024 09:30

TVM Capital Healthcare Announces the Closing of its Saudi Arabia-Focused TVM Healthcare Afiyah Fund

TVM Capital Healthcare, an international healthcare expansion and growth capital investor, today announced the closing of the TVM Healthcare Afiyah Fund LP at approximately USD 250 million, its second

May 29, 2024 11:55

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

The international pharmaceutical BCorp company Ferrer continues to strengthen its focus on pulmonary vascular and interstitial lung diseases by announcing the expansion of its current distribution agr

May 28, 2024 14:58

Oncocross and JW Pharmaceutical Team Up on AI-powered Drugs for Cancer and Regeneration

Oncocross, an AI biotech company specializing in drug discovery and development, announced that it has signed a joint research agreement with JW Pharmaceutical to develop new drugs based on the AI pl

May 28, 2024 14:30

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

High-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favoured datopotamab de

May 26, 2024 10:55

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization applications (MAAs) for HLX14, an in

May 24, 2024 14:10

Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024

Merck, a leading science and technology company, today announced new research from the company’s diverse oncology portfolio will be presented at the 2024 American Society of Clinical Oncology (ASCO) A

May 23, 2024 14:36

Galderma Launches Restylane® VOLYME™ in China - One of the World’s Fastest Growing Aesthetics Markets

Galderma (SWX:GALD) announced today the launch of its hyaluronic acid injectable filler, Restylane® VOLYME™ in China. The company is also introducing its complementary Shape Up Holistic Individualized

May 22, 2024 17:10

Medscape Education and KDIGO Nephrology Collaboration Accelerates Improvements to Patient Care

Ahead of the 61st European Renal Association (ERA) Congress, Medscape Education and KDIGO (Kidney Disease: Improving Global Outcomes) announce an educational collaboration through a series of webinars

May 22, 2024 14:30

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

Today AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth in its existing oncology,

May 22, 2024 13:40

QPS Expands Clinic in Miami, Florida to Accommodate Increasing Demand for Obesity Trials

QPS, a leading global contract research organization (CRO), continues to expand and align its full-service preclinical, bioanalysis, and clinical capabilities with the evolution of demand for clinical

May 22, 2024 11:35

Leading Pharmaceutical Company Selects Kinaxis to Cure Supply Chain Headaches

Kinaxis (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.kinaxis.com%2Fen&esheet=54001339&newsitemid=20240521977758&lan=en-US&anchor=Kinaxis&index=1&md5=5f9eae6c7e7cdf798bb35930e

May 22, 2024 11:00

Carestream Introduces Image Suite MR 10 Software to Enhance Imaging Experience for CR and DR Imaging Systems

Carestream launches its Image Suite MR 10 Software to help deliver a boost to productivity and efficiency while enabling a more user-friendly imaging experience for radiographers. Carestream’s Imag

May 16, 2024 16:44

New Award Programme From Oral-B and the International Association for Disability and Oral Health (iADH) Champions Disability Positive Dental Practices Across Europe

Today, on Global Accessibility Awareness Day (GAAD), Oral-B proudly launches the Disability Champions Award Programme as part of its ongoing mission to make oral care more accessible to everybody. In

May 16, 2024 16:00

FinalSpark Launches the First Remote Research Platform Using Human Neurons for Biocomputing

FinalSpark, a pioneering Swiss biocomputing startup, has launched the first-ever online platform enabling global researchers to conduct experiments remotely on biological neurons in vitro. The platfor

May 16, 2024 14:20

Optiscan Signs Know-How Agreement with Mayo Clinic

Optiscan Imaging Limited (ASX:OIL) (‘Optiscan’ or ‘The Company’) is pleased to announce that it has entered into a collaboration through a know-how agreement with Mayo Clinic to develop a digital conf

May 16, 2024 13:09

Todd Clegg Named Carestream’s Chief Executive Officer

Carestream, a world-leading provider of medical imaging systems and non-destructive testing solutions, announced that Todd Clegg has been named CEO and appointed to the Board of Directors, effective i

May 16, 2024 10:03

MRM Health to Present Positive Clinical Data from MH002 in Ulcerative Colitis at Digestive Disease Week (DDW)

MRM Health NV, a clinical-stage biopharmaceutical company developing innovative therapeutics for inflammatory, CNS and metabolic diseases, today announced it will present positive data for its lead as

May 15, 2024 10:30

Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting

Takeda (TSE: 4502/NYSE:TAK) (https://www.takeda.com/investors/overview/) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the Am

May 14, 2024 14:10

GRAMINEX®, L.L.C. Final Publication of a Peer Reviewed Clinical Trial with Graminex® Flower Pollen Extract Focusing on Women’s Urinary Incontinence in Current Urology.

Graminex®, L.L.C. is pleased to announce publication of a peer reviewed clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health in Current Urology. The

May 14, 2024 09:55

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease

Takeda (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2F&esheet=53983823&newsitemid=20240510475155&lan=en-US&anchor=Takeda&index=1&md5=4a403ee030780c54b5ebde46e786f5

May 13, 2024 10:20

Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion

Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2023 (period ended March 31, 2024), delivering its Management Guidance for Core Operating Profit and exceeding its Manage

May 10, 2024 14:55

BeiGene Reports First Quarter 2024 Financial Results and Business Updates

BeiGene (https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.beigene.com%2F&esheet=53978747&newsitemid=20240508878785&lan=en-US&anchor=BeiGene&index=1&md5=289a1210b11d33d3f6dbd570f8e

May 09, 2024 15:40

LC-Plasma-based Vaccine Research Selected for SCARDA Project

Kirin Holdings Company, Limited (Kirin Holdings)(TOKYO:2503) and National Institute of Infectious Diseases (NIID) are jointly conducting studies to investigate the protective efficacy of L. lactis str

May 09, 2024 13:55

Study Suggests Critical Link Between Residual FLT3-ITD Mutations in Remission and Post-Transplant Outcomes in AML

A groundbreaking research study,[1] sequencing DNA samples from the Pre-MEASURE study[2] strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood

May 07, 2024 14:35

Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in Four Additional Countries

Galderma today announced that it has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic derm

May 07, 2024 11:30

Parse Biosciences Launches Single Cell Immune Profiling Products

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the availability of Evercode™ BCR and the expansion of its existing Evercode™ TCR pro

May 03, 2024 10:35

Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer

Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 bi

News by Region

News by Industry

The largest press release distribution network in Korea

Global PR service

News by region

News by industry